<p>红杉金融顾问公司在最近向证券交易委员会（SEC）提交的 13F 表格中披露，其在阿里拉姆制药公司（NASDAQ:ALNY - 免费报告）的持股在第二季度增加了 15.4%。该基金在本季度购买了额外的 522 股后，持有该生物制药公司 3,917 股股票。根据其最近向证券交易委员会（SEC）提交的文件，红杉金融顾问公司在阿里拉姆制药的持股价值为 1,277,000 美元。</p>
<ul>
<li>阿里拉姆股票飙升 65%：了解背后的原因</li>
</ul>
<p>其他几家对冲基金最近也调整了对该公司的持股。Allspring Global Investments Holdings LLC 在第二季度将其在阿里拉姆制药的股份增加了 15.2%。Allspring Global Investments Holdings LLC 目前持有 312,216 股该生物制药公司的股票，价值为 100,552,000 美元，此前在上个季度购买了 41,292 股。OFI Invest Asset Management 在第二季度将其在阿里拉姆制药的股份增加了 26.2%。OFI Invest Asset Management 目前持有 381 股该生物制药公司的股票，价值为 124,000 美元，此前在上个季度购买了 79 股。先锋个性化指数管理公司在第二季度将其在阿里拉姆制药的股份增加了 47.3%。先锋个性化指数管理公司目前持有 13,390 股该生物制药公司的股票，价值为 4,368,000 美元，此前在上个季度购买了 4,302 股。Sivik Global Healthcare LLC 在第二季度购买了阿里拉姆制药的新头寸，价值为 2,120,000 美元。最后，阿伯丁集团在第二季度将其在阿里拉姆制药的持股增加了 1.5%。阿伯丁集团目前持有 218,624 股该生物制药公司的股票，价值为 70,364,000 美元，此前在此期间增加了 3,239 股。对冲基金和其他机构投资者持有该公司 92.97% 的股票。</p>
<h2>内部人士下注</h2>
<p>在其他消息中，执行副总裁 Pushkal Garg 在 10 月 3 日（星期五）出售了 3,022 股公司的股票。该股票以平均价格 451.48 美元出售，总价值为 1,364,372.56 美元。出售完成后，该执行副总裁直接持有 20,221 股公司的股票，价值为 9,129,377.08 美元。这笔交易代表其持股减少了 13.00%。该交易已在向证券交易委员会提交的文件中披露，相关文件可在此链接查看。此外，执行副总裁 Tolga Tanguler 在 10 月 2 日（星期四）出售了 1,405 股公司的股票。该股票以平均价格 452.05 美元出售，总价值为 635,130.25 美元。出售后，该执行副总裁直接持有 27,438 股公司的股票，价值为 12,403,347.90 美元。这代表其持股减少了 4.87%。该出售的披露信息可以在这里找到。在过去三个月中，内部人士出售了 98,144 股公司股票，价值为 44,160,261 美元。目前公司内部人士持有 1.50% 的股票。</p>
<h2>阿里拉姆制药价格表现</h2>
<ul>
<li>3 家生物科技巨头在行业反弹中蓄势待发</li>
</ul>
<p>阿里拉姆制药的股票在星期五开盘价为 481.07 美元。该股票的 50 日移动平均线为 455.04 美元，200 日移动平均线为 350.64 美元。阿里拉姆制药公司 12 个月低点为 205.87 美元，12 个月高点为 488.39 美元。该公司的市值为 630.6 亿美元，市盈率为-194.77，贝塔系数为 0.36。该公司的流动比率为 2.80，速动比率为 2.75，债务股本比率为 4.10。</p>
<p>阿里拉姆制药（NASDAQ:ALNY - 获取免费报告）最近在 7 月 31 日（星期四）公布了季度财报。该生物制药公司报告本季度每股收益为 0.32 美元，超出分析师一致预期的-0.54 美元，超出幅度为 0.86 美元。阿里拉姆制药的股本回报率为-273.52%，净利润率为-12.96%。该公司本季度的收入为 7.7369 亿美元，而分析师预期为 6.3354 亿美元。在去年同期，该公司每股收益为-0.13 美元。该公司的收入同比增长 17.3%。阿里拉姆制药已将其 2025 财年的指引设定为每股收益。研究分析师平均预计阿里拉姆制药公司本财年的每股收益为-1.7。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>Argenx 的 28% 飙升及其有前景的产品提升了投资者信心</li>
</ul>
<p>几位分析师最近对 ALNY 股票发表了评论。富国银行将阿里拉姆制药的目标价从 333.00 美元上调至 395.00 美元，并在 8 月 1 日（星期五）的报告中给予该股票 “持平” 评级。加拿大丰业银行将阿里拉姆制药的目标价从 342.00 美元上调至 450.00 美元，并在 8 月 1 日（星期五）的报告中给予该股票 “行业表现优于大盘” 评级。杰富瑞金融集团将阿里拉姆制药的目标价从 328.00 美元上调至 384.00 美元，并在 7 月 7 日（星期一）的报告中给予该股票 “买入” 评级。Truist Financial 在 7 月 21 日（星期一）的报告中开始覆盖阿里拉姆制药。他们给予该公司 “买入” 评级和 385.00 美元的目标价。最后，Weiss Ratings 在 10 月 8 日（星期三）的报告中重申了对阿里拉姆制药股票的 “卖出（d-）” 评级。24 位分析师对该股票给予 “买入” 评级，3 位给予 “持有” 评级，1 位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，平均目标价为 457.08 美元。</p>
<p><strong>查看我们关于阿里拉姆制药的最新研究报告</strong></p>
<h2>阿里拉姆制药简介</h2>
<p>（免费报告）</p>
<p>阿里拉姆制药公司是一家生物制药公司，专注于基于核糖核酸干扰技术的新型治疗药物的发现、开发和商业化。其上市产品包括用于治疗成人遗传性转甲状腺素介导的淀粉样变性多发性神经病的 ONPATTRO（patisiran）；用于治疗成人 hATTR 淀粉样变性伴多发性神经病的 AMVUTTRA；用于治疗成人急性肝脏卟啉症的 GIVLAARI；以及用于治疗原发性高草酸尿症 1 型的 OXLUMO。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过阿里拉姆制药</li>
<li>罗素 2000 指数，投资者如何利用它进行盈利交易</li>
<li>Salesforce 期待已久的拐点已到：继续上涨！</li>
<li>基础材料股票投资</li>
<li>Rocket Lab USA 获得华尔街的认可：现在是买入时机吗？</li>
<li>如何做空纳斯达克：简单易懂的指南</li>
<li>Archer 以战略性举措收购竞争对手的专利宝藏</li>
</ul>
<p><strong>想知道其他对 ALNY 感兴趣的对冲基金持有哪些股票吗？</strong> 请访问 HoldingsChannel.com，获取阿里拉姆制药公司（NASDAQ:ALNY - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxOWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxOWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在阿里拉姆制药吗？</h2>
<p>在考虑阿里拉姆制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而阿里拉姆制药并不在其中。</p>
<p>虽然阿里拉姆制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

阿里拉姆制药

<p>Sequoia Financial Advisors LLC 在第二季度将其在阿里拉姆制药的股份增加了 15.4%，目前持有 3,917 股，价值 128 万美元。其他对冲基金也增加了他们的持股，机构投资者持有该公司 92.97% 的股份。最近的内部销售包括执行副总裁 Pushkal Garg 出售了 3,022 股，执行副总裁 Tolga Tanguler 出售了 1,405 股。阿里拉姆的股票开盘价为 481.07 美元，市值为 630.6 亿美元，最近一个季度的收入为 7.7369 亿美元，超出了分析师的预期</p>

<p>Sequoia Financial Advisors LLC lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 15.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,917 shares of the biopharmaceutical company's stock after purchasing an additional 522 shares during the quarter. Sequoia Financial Advisors LLC's holdings in Alnylam Pharmaceuticals were worth $1,277,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>红杉金融顾问公司在最近向证券交易委员会（SEC）提交的 13F 表格中披露，其在阿里拉姆制药公司（NASDAQ:ALNY - 免费报告）的持股在第二季度增加了 15.4%。该基金在本季度购买了额外的 522 股后，持有该生物制药公司 3,917 股股票。根据其最近向证券交易委员会（SEC）提交的文件，红杉金融顾问公司在阿里拉姆制药的持股价值为 1,277,000 美元。</p>
</div><ul>
<li>Alnylam Stock Soars 65%: Find Out What’s Behind the Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>阿里拉姆股票飙升 65%：了解背后的原因</li>
</ul>
</div><p>Several other hedge funds have also recently modified their holdings of the business. Allspring Global Investments Holdings LLC raised its stake in shares of Alnylam Pharmaceuticals by 15.2% in the second quarter. Allspring Global Investments Holdings LLC now owns 312,216 shares of the biopharmaceutical company's stock worth $100,552,000 after purchasing an additional 41,292 shares during the last quarter. OFI Invest Asset Management raised its stake in shares of Alnylam Pharmaceuticals by 26.2% in the second quarter. OFI Invest Asset Management now owns 381 shares of the biopharmaceutical company's stock worth $124,000 after purchasing an additional 79 shares during the last quarter. Vanguard Personalized Indexing Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 47.3% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,390 shares of the biopharmaceutical company's stock worth $4,368,000 after purchasing an additional 4,302 shares during the last quarter. Sivik Global Healthcare LLC purchased a new position in shares of Alnylam Pharmaceuticals in the second quarter worth $2,120,000. Finally, Aberdeen Group plc grew its holdings in shares of Alnylam Pharmaceuticals by 1.5% in the second quarter. Aberdeen Group plc now owns 218,624 shares of the biopharmaceutical company's stock worth $70,364,000 after acquiring an additional 3,239 shares during the period. Hedge funds and other institutional investors own 92.97% of the company's stock.</p>
<div class="lb-trans"><p>其他几家对冲基金最近也调整了对该公司的持股。Allspring Global Investments Holdings LLC 在第二季度将其在阿里拉姆制药的股份增加了 15.2%。Allspring Global Investments Holdings LLC 目前持有 312,216 股该生物制药公司的股票，价值为 100,552,000 美元，此前在上个季度购买了 41,292 股。OFI Invest Asset Management 在第二季度将其在阿里拉姆制药的股份增加了 26.2%。OFI Invest Asset Management 目前持有 381 股该生物制药公司的股票，价值为 124,000 美元，此前在上个季度购买了 79 股。先锋个性化指数管理公司在第二季度将其在阿里拉姆制药的股份增加了 47.3%。先锋个性化指数管理公司目前持有 13,390 股该生物制药公司的股票，价值为 4,368,000 美元，此前在上个季度购买了 4,302 股。Sivik Global Healthcare LLC 在第二季度购买了阿里拉姆制药的新头寸，价值为 2,120,000 美元。最后，阿伯丁集团在第二季度将其在阿里拉姆制药的持股增加了 1.5%。阿伯丁集团目前持有 218,624 股该生物制药公司的股票，价值为 70,364,000 美元，此前在此期间增加了 3,239 股。对冲基金和其他机构投资者持有该公司 92.97% 的股票。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, EVP Pushkal Garg sold 3,022 shares of the firm's stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $451.48, for a total value of $1,364,372.56. Following the completion of the sale, the executive vice president directly owned 20,221 shares of the company's stock, valued at $9,129,377.08. This trade represents a 13.00% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, EVP Tolga Tanguler sold 1,405 shares of the firm's stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $635,130.25. Following the sale, the executive vice president directly owned 27,438 shares of the company's stock, valued at $12,403,347.90. This represents a 4.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 98,144 shares of company stock worth $44,160,261. 1.50% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他消息中，执行副总裁 Pushkal Garg 在 10 月 3 日（星期五）出售了 3,022 股公司的股票。该股票以平均价格 451.48 美元出售，总价值为 1,364,372.56 美元。出售完成后，该执行副总裁直接持有 20,221 股公司的股票，价值为 9,129,377.08 美元。这笔交易代表其持股减少了 13.00%。该交易已在向证券交易委员会提交的文件中披露，相关文件可在此链接查看。此外，执行副总裁 Tolga Tanguler 在 10 月 2 日（星期四）出售了 1,405 股公司的股票。该股票以平均价格 452.05 美元出售，总价值为 635,130.25 美元。出售后，该执行副总裁直接持有 27,438 股公司的股票，价值为 12,403,347.90 美元。这代表其持股减少了 4.87%。该出售的披露信息可以在这里找到。在过去三个月中，内部人士出售了 98,144 股公司股票，价值为 44,160,261 美元。目前公司内部人士持有 1.50% 的股票。</p>
</div><h2>Alnylam Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>阿里拉姆制药价格表现</h2>
</div><ul>
<li>3 biotech powerhouses poised to thrive amid sector rebound</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家生物科技巨头在行业反弹中蓄势待发</li>
</ul>
</div><p>Shares of Alnylam Pharmaceuticals stock opened at $481.07 on Friday. The stock has a 50 day moving average of $455.04 and a 200 day moving average of $350.64. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $488.39. The firm has a market cap of $63.06 billion, a PE ratio of -194.77 and a beta of 0.36. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10.</p>
<div class="lb-trans"><p>阿里拉姆制药的股票在星期五开盘价为 481.07 美元。该股票的 50 日移动平均线为 455.04 美元，200 日移动平均线为 350.64 美元。阿里拉姆制药公司 12 个月低点为 205.87 美元，12 个月高点为 488.39 美元。该公司的市值为 630.6 亿美元，市盈率为-194.77，贝塔系数为 0.36。该公司的流动比率为 2.80，速动比率为 2.75，债务股本比率为 4.10。</p>
</div><p>Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company had revenue of $773.69 million during the quarter, compared to analyst estimates of $633.54 million. During the same period in the prior year, the company earned ($0.13) earnings per share. The firm's revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>阿里拉姆制药（NASDAQ:ALNY - 获取免费报告）最近在 7 月 31 日（星期四）公布了季度财报。该生物制药公司报告本季度每股收益为 0.32 美元，超出分析师一致预期的-0.54 美元，超出幅度为 0.86 美元。阿里拉姆制药的股本回报率为-273.52%，净利润率为-12.96%。该公司本季度的收入为 7.7369 亿美元，而分析师预期为 6.3354 亿美元。在去年同期，该公司每股收益为-0.13 美元。该公司的收入同比增长 17.3%。阿里拉姆制药已将其 2025 财年的指引设定为每股收益。研究分析师平均预计阿里拉姆制药公司本财年的每股收益为-1.7。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li>
</ul>
<div class="lb-trans"><ul>
<li>Argenx 的 28% 飙升及其有前景的产品提升了投资者信心</li>
</ul>
</div><p>Several analysts recently commented on ALNY shares. Wells Fargo &amp; Company lifted their price objective on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the stock an &#34;equal weight&#34; rating in a report on Friday, August 1st. Scotiabank lifted their price objective on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a &#34;sector outperform&#34; rating in a report on Friday, August 1st. Jefferies Financial Group lifted their price objective on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, July 7th. Truist Financial started coverage on Alnylam Pharmaceuticals in a report on Monday, July 21st. They issued a &#34;buy&#34; rating and a $385.00 price objective for the company. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, October 8th. Twenty-four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $457.08.</p>
<div class="lb-trans"><p>几位分析师最近对 ALNY 股票发表了评论。富国银行将阿里拉姆制药的目标价从 333.00 美元上调至 395.00 美元，并在 8 月 1 日（星期五）的报告中给予该股票 “持平” 评级。加拿大丰业银行将阿里拉姆制药的目标价从 342.00 美元上调至 450.00 美元，并在 8 月 1 日（星期五）的报告中给予该股票 “行业表现优于大盘” 评级。杰富瑞金融集团将阿里拉姆制药的目标价从 328.00 美元上调至 384.00 美元，并在 7 月 7 日（星期一）的报告中给予该股票 “买入” 评级。Truist Financial 在 7 月 21 日（星期一）的报告中开始覆盖阿里拉姆制药。他们给予该公司 “买入” 评级和 385.00 美元的目标价。最后，Weiss Ratings 在 10 月 8 日（星期三）的报告中重申了对阿里拉姆制药股票的 “卖出（d-）” 评级。24 位分析师对该股票给予 “买入” 评级，3 位给予 “持有” 评级，1 位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，平均目标价为 457.08 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Alnylam Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们关于阿里拉姆制药的最新研究报告</strong></p>
</div><h2>Alnylam Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>阿里拉姆制药简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.</p>
<div class="lb-trans"><p>阿里拉姆制药公司是一家生物制药公司，专注于基于核糖核酸干扰技术的新型治疗药物的发现、开发和商业化。其上市产品包括用于治疗成人遗传性转甲状腺素介导的淀粉样变性多发性神经病的 ONPATTRO（patisiran）；用于治疗成人 hATTR 淀粉样变性伴多发性神经病的 AMVUTTRA；用于治疗成人急性肝脏卟啉症的 GIVLAARI；以及用于治疗原发性高草酸尿症 1 型的 OXLUMO。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Alnylam Pharmaceuticals</li>
<li>Russell 2000 Index, How Investors Use it For Profitable Trading</li>
<li>Salesforce’s Long-Awaited Inflection is Here: Rally On!</li>
<li>Basic Materials Stocks Investing</li>
<li>Rocket Lab USA Receives Wall Street Validation: Time to Buy?</li>
<li>How to Short Nasdaq: An Easy-to-Follow Guide</li>
<li>Archer Buys Rival's Patent Treasure Trove in Strategic Move</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过阿里拉姆制药</li>
<li>罗素 2000 指数，投资者如何利用它进行盈利交易</li>
<li>Salesforce 期待已久的拐点已到：继续上涨！</li>
<li>基础材料股票投资</li>
<li>Rocket Lab USA 获得华尔街的认可：现在是买入时机吗？</li>
<li>如何做空纳斯达克：简单易懂的指南</li>
<li>Archer 以战略性举措收购竞争对手的专利宝藏</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ALNY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 ALNY 感兴趣的对冲基金持有哪些股票吗？</strong> 请访问 HoldingsChannel.com，获取阿里拉姆制药公司（NASDAQ:ALNY - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxOWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ALNY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Alnylam Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在阿里拉姆制药吗？</h2>
</div><p>Before you consider Alnylam Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑阿里拉姆制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而阿里拉姆制药并不在其中。</p>
</div><p>While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然阿里拉姆制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

红杉金融顾问有限责任公司增持了阿里拉姆制药公司（股票代码：$ALNY）的股份